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Abstract
Chagas disease, or American trypanosomiasis, is a parasitic disease of the 
Americas. In nature, Trypanosoma cruzi is transmitted through various species 
of triatomine bugs. However, non-vectorial transmission can also occur, such as 
transmission through blood products or by transplanting infected organs, by verti-
cal transmission, and lately by oral route. Currently, Chagas disease affects approxi-
mately 6–7 million people worldwide, and the process of urbanization in Latin 
America and migratory movements from endemic countries have led to Chagas dis-
ease being diagnosed in areas where the infection is not endemic. There are several 
methods for diagnosing Chagas disease. Some of these are mostly used for research 
purposes, while others are used in routine diagnostic laboratories. According to the 
World Health Organization (WHO), chronic Chagas disease diagnosis is based on 
two serological techniques. To establish a definitive diagnosis, the results must be 
concordant. In the case of discordances, the WHO proposes repeating serology in a 
new sample, and if results remain inconclusive, a confirmatory test should be per-
formed. This chapter shows aspects of the diagnosis of Chagas disease, which varies 
in its sensitivity and specificity, and its use depends on the geographical location, 
the available resources, and the purpose of the diagnosis.
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1. Introduction
The infection caused by the protozoan parasite Trypanosoma cruzi leads to 
Chagas disease, with an estimated 6–7 million infected people and nearly 60 million 
at risk of infection [1, 2]. Chagas disease ranks among the world’s most neglected 
diseases and is considered to be the parasitic infection with the greatest socioeco-
nomic impact in Latin America, being responsible for an estimated US$ 1.2 billion 
in lost productivity annually [3]. It is a disease that a century after its discovery 
still requires appropriate control measures, effective treatment, and especially 
an accurate diagnosis. This disease is endemic to most countries in Latin America 
[4], but it has now become more important in other regions. The increasing pres-
ence of Chagas in non-endemic areas, as well as the resurgence of the disease in 
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endemic countries, has been a major focus of attention in recent years [5] and, over 
the last 40 years, has become a global health concern due to the huge migration 
flows from Latin America to Europe, United States, Canada, and Japan. In Europe, 
most migrants from Chagas disease-endemic areas are concentrated in Spain, Italy, 
France, United Kingdom, and Switzerland (Figure 1) [6]. The flagellate protozoa  
T. cruzi is usually transmitted through infected feces and/or urine excreted by 
triatomines (Hemiptera: Reduviidae) during blood feeding. However, this is a 
nonlinear phenomenon, as mammals can be exposed to infection multiple times 
through distinct routes [7]; the main routes of transmission of the parasite are 
through the insect vector, blood transfusion, transplants of organs, congenital via, 
orally and it is now reported that the infection is capable of being transmitted sexu-
ally (Figure 2). In addition, the fact that Chagas disease can be transmitted sexu-
ally, along with the migration problems of individuals affected with Chagas disease 
to countries that were previously not endemic, and travel to endemic countries, has 
direct implications for public health for the spread of this disease [8], the transmis-
sion through vector only occurs in endemic areas for this disease. In non-endemic 
countries, the main routes of transmission are blood and congenital transmission 
[9–11]. T. cruzi has a high genetic diversity, which is why it has been classified into 
discrete typing units (DTU): TCI-TcVI, in addition, of a genotype associated with 
bats (TcBat); this classification was made based on different characteristics such as 
geographical distribution and clinical manifestations of the disease, among others. 
As TcI is the most widely distributed DTU and with a wide genetic diversity, it has 
been divided into domestic and sylvatic genotypes (TcIDom and TcISyl) [12].
The disease presents two phases. In the acute phase, ranging from the time of 
infection until about 6 weeks after this, patients present a high parasitemia and 
may show nonspecific symptoms, such as fever and headache. During the chronic 
phase, which can last up to 30 years, approximately 30% of patients develop cardiac 
complications such as arrhythmias and cardiomyopathy, and 10% of patients may 
present intestinal complications, especially constipation, or neurological complica-
tions. However, the chronic phase is characterized by the absence of symptoms 
in most patients (Figure 3) [1, 13]. The latter, coupled with the fact that patients 
can be found in non-endemic areas where the disease is unknown, represents an 
added difficulty for the diagnosis of infection [14]. The effectiveness of methods 
for diagnosing infectious diseases depends on their sensitivity and specificity for 
the unambiguous detection of the presence of the pathogen or the specific host 
Figure 1. 
Distribution of Chagas Disease (WHO: Estimated data 2010).
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response in response to infection. New technologies based on molecular biol-
ogy have enabled the identification of biomarkers exclusive of infectious agents, 
molecules involved in interactions with their hosts, and of the host molecules which 
mediate response to infection [15]. Infectious diseases remain a major public health 
problem worldwide. In this scenario, the immunodiagnostic method has been and 
will remain an essential tool to demonstrate the presence of infection in patients, 
for disease prognosis, for monitoring clinical studies, and, also, as tools to monitor 
the success of strategies for control and epidemiological monitoring [16]. Finally, 
Figure 2. 
Main routes of transmission of the Trypanosoma cruzi.
Figure 3. 
Chagas disease has two stages or clinical phases: an acute phase and a chronic phase. People (from 70 to 80% 
of those infected) are asymptomatic throughout their lives, but from 20 to 30% of those affected, this disease 
progresses to chronic symptoms.
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this chapter was conceived to the current need for an accurate diagnosis for Chagas 
disease, since the correct diagnosis is a priority not only to identify the people who 
should receive the appropriate treatment but also to reduce and prevent the risk of 
transmission through a blood transfusion or an organ transplant.
2. Why the need for an accurate diagnosis for Chagas disease
One of the limitations for the prevention and control of neglected tropical dis-
eases is that the sociocultural aspects associated with diseases are ignored. Cases of 
Chagas disease in endemic areas occur in specific contexts marked by sociocultural, 
political, and economic circumstances. In addition, in the case of Chagas disease, 
the absence of symptoms in most cases, the lack of ability to detect and/or identify 
the disease, the lack of information on services and immigration policies, affect. 
It is very important to be able to obtain prevention and control measures for the 
disease, even in non-endemic countries [17]. Understanding this behavior can allow 
to guide health policies to combat these types of diseases, where indigenous groups 
and children are considered especially vulnerable groups.
2.1 The current status of the diagnosis of Chagas disease
Diagnostic methods for T. cruzi can be included in three main groups: parasitologi-
cal, serological, and molecular (Figure 4). Parasitological methods aim to visualize the 
presence of parasites, and their sensitivity varies depending on the stage of infection 
[18]. For diagnosis of the disease in the phase where the parasitemia is very low, immu-
nological methods (serological) are based primarily on the search for G antibodies 
(IgG) anti-T. cruzi in the blood of patients and their colorimetric reaction visible in the 
case that the blood of the patients contains the antibodies. [19]. The most commonly 
used methods are ELISA test (sensitivity = 94–100%, specificity = 96–100%), indirect 
hemagglutination (HAI, sensitivity = 88–99%, specificity = 96–100%), and indirect 
immunofluorescence (IFI, sensitivity = 98%, specificity = 98%). Despite being highly 
sensitive and specific, serological tests can have some cross-reactivity.
Figure 4. 
Diagnostic methods for T. cruzi.
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Another technique based on the search for anti-T. cruzi antibodies is the 
Western blot, which has been used in the diagnosis of Chagas disease using mainly 
 excretion-secretion antigens and in some cases recombinant proteins. In the 
reported works, the Western blot has been used mainly to confirm the serologi-
cal results obtained when other serological techniques are discordant or when 
there are cases of cross-reaction with Leishmania, and it has been observed that 
the technique possesses a high sensitivity and specificity. Although this test is not 
used routinely, and it is not considered as a substitute for conventional serological 
tests, it may be useful as an additional diagnostic test or for field studies [20–22]. 
Detection of parasite DNA using molecular diagnostic tools could be an alternative 
or complement to current diagnostic methods, but its implementation in endemic 
regions remains limited, due to lack of standardization, complexity, lack of clinical 
evidence, and the cost of implementation [23].
The application of molecular biological techniques has allowed the production of 
specific antigens in large quantities for use in immunologic techniques, including 
recombinant antigens and synthetic peptides [24]. Molecular biology methods are 
characterized by a high specificity and sensitivity, particularly during the acute 
phase, and hybridization techniques have been used for the detection of specific 
DNA fragments of the parasite genome by polymerase chain reaction (PCR) [25–27]. 
One of the major limitations of the PCR technique in the diagnosis of Chagas disease 
is its low sensitivity in the chronic phase due to the very low level of circulating 
parasites, since these are confined to tissues [28, 29]. However, it is important to note 
that the sensitivity of PCR is also influenced by the method of DNA extraction and 
the volume of blood that is used for DNA extraction [30]. Parasite detection from 
organ biopsies is indeed more successful during chronic infection when parasites 
sequester within organs; however, this technique is impractical because biopsies are 
not easily collected [31, 32]. Some authors proposed that circulating parasite anti-
gens could be used as highly specific biomarkers of infection by T. cruzi as observed 
in mouse models [33]. Serum proteins have also been proposed as markers of 
Chagasic patients [34]. However, diagnosis remains mostly focused on the identifica-
tion of antibodies against the parasite (Table 1) [35]. The nature of the antigens used 
in anti-T. cruzi assays is critical for the specificity of the assay, particularly in the case 
of individuals infected with related protozoan parasites such as Leishmania, as 
epitopes may cross-react with crude T. cruzi antigens [36]. Various types of serologic 
tests are currently used to establish the diagnosis of Chagas disease (Table 2), based 
on total parasite extracts and/or recombinant antigens [37, 38]. These serological 
assays for detecting antibodies to T. cruzi are generally classified as screening or 
confirmatory assays (Table 2). First-line screening assays provide the presumptive 
identification of antibody-reactive specimens, and supplemental assays are used to 
confirm whether samples found reactive with a particular screening assay do indeed 
contain antibodies specific to T. cruzi. When a single screening assay is used for 
testing in a population with a very low prevalence of Chagas disease, the probability 
that an individual is infected when a reactive test result is obtained (i.e., the positive 
predictive value) is very low, since the majority of individuals with reactive results 
are not infected. This problem occurs even when an assay with high specificity is 
used. Accuracy can be improved if a second supplemental assay is used to retest all 
those specimens found reactive by the first assay. Those found non-reactive by the 
assay are considered negative for antibodies to T. cruzi. Serum/plasma samples with 
low antibody titer are frequently found in individuals from endemic regions. In 
general, those samples are difficult to confirm and give a definitive final status.  
The clinical significance of these samples and associated potential risk of transmis-
sion by an individual presenting with low antibody titer is also little understood. 
These could represent individuals spontaneous cure or treated by current 
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antiparasitic medication [39] or have cross-reactivity with other agents such as 
Leishmania [40]. To date, and according to the WHO, an individual is diagnosed as 
infected with T. cruzi in the chronic phase of the disease when the results of two 
serological tests are positive, due to the different immunogenicity of different strains 
of the parasite, different immune responses between patients, and the existence of 
cross-reactions with other trypanosomatids coexisting in endemic areas when using 
crude parasite antigens [16, 38]. When inconclusive or discordant results appear, a 
third technique [38] or additional samples are required [41]. However, during the 
diagnosis of the disease, we must take into account certain conditions and/or 
variables that are not directly dependent on the design and development of the test; 
as in the case of the host response, this depends partly on the strain of parasite and 
secondly on the genetic background of the host [42]. Moreover, the existence of the 
“immunological memory” in models where there was a parasitological cure suggests 
that parasite antigens may persist in some organs, which could be inducing the 
production of antibodies, regardless of the presence of live parasite [43, 44]. In 
patients treated during the chronic phase, the objective is to analyze a tendency for 
negativization of the serological tests, which requires to monitor patients for many 
years following treatment. This has brought controversies regarding the criterion of 
a serologic cure [45, 46]. Some researchers believe that a reduction in antibody titers 
after a prolonged time can be considered as a criterion of cure, in contrast to others 
who recommend total negativization of serological tests [47]. In areas where Chagas 
disease is endemic, the choice among ELISA, IIF, or IHA for serological testing is 
based on availability [31, 32, 38, 48]. However, these techniques may be unspecific as 
they can cross-react with other parasites [49]. Because of this cross-reaction, the use 
of antigen secretion/excretion of parasite in diagnostic tests has been proposed. It 
has been shown that proteins from trypomastigotes are better antigens to detect 
antibodies against the parasite; however, most antigens used for immunological tests 
are total protein extracts derived from epimastigotes, because of the ease of 
Diagnostic methods in the acute phase
Direct methods without concentration
Direct methods of concentration
• Microhematocrit
• Strout test
Diagnostic methods in the chronic phase
Serology
• ELISA
• Indirect immunofluorescence
• Indirect hemagglutination
Other parasitological and molecular biology methods*
• Xenodiagnostic
• In vitro culture
• PCR
*Can be used in any phase, with low parasitemia, and is not detected by other methods.
Table 1. 
Diagnoses for chagas disease.
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Test Antigen Manufacturer Country
Immunoenzymatic assay
AccuDiag™ Chagas ELISA Kit NI Diagnostic Automation/
Cortez Diagnostics, Inc.
USA
ImmunoComb® II Chagas Ab Kit RA Alere Inc. Germany
Anti-Chagas IgG ELISA Kit NI Abcam United 
Kingdom
Abbott ESA Chagas Purified antigens Abbott Laboratories USA
Abbott PRISM Chagas Purified antigens Abbott Laboratories USA
T. cruzi Ab (Chagas) Bioars Argentina
EIAgen Trypanosoma cruzi Ab Total extract Adaltis Italy
Chagas screen ELISA Cytoplasmic 
membrane 
antigen
Wiener lab Argentina
Chagas ELISA IgG + IgM RA Vircell Spain
Pathozyme Chagas RA Omega Diagnostics 
Limited
Scotland
Chagas Rec ELISA RA Human Diagnostics 
Worldwide
Germany
Chagas ELISA Total extract Ebram Produtos 
Laboratoriais Ltda
Brazil
Chagatek ELISA Purified antigens Laboratório Lemos SRL Argentina
NovaLisa Chagas (Trypanosoma 
cruzi)
NI NovaTec 
Immundiagnostica
Germany
Premier Chagas IgG ELISA test Purified antigens Meridian Diagnostics USA
Test ELISA para Chagas Total extract 
strain (Tulahuén 
and Mn)
BIOSChile Chile
Bio-Manguinhos EIA Total extract/RP Bio-Manguinhos Brazil
IVD ELISA NI IVD Research Inc. USA
DRG®Trypanosoma cruzi IgG NI DRG International Inc. USA
Chagas IgG ELISA RA Gull Laboratories Inc./
Meridian Bioscience Inc.
USA
Cellabs T. cruzi IgG CELISA NI Cellabs Pty Ltd. Australia
BIOELISACRUZI Total extract Biolab-Mérieux Brazil
Dia Kit Bio-Chagas RA Gador SA Argentina
BIOZIMA Chagas kit Purified antigens Laboratório Lemos SRL Argentina
Abbott Chagas Anticorpos EIA RA Abbott Laboratories USA
Cruzi TEST ELISA NI GenCell Biosystems Ireland
Chagas test IICS, ELISA Total extract (Y 
strain)
IICS Univ de Asunción Paraguay
HBK 401 Hemobio Chagas Total extract Embrabio Brazil
Chagatest ELISA Total extract/RP Wiener lab Argentina
Bioelisa Chagas Synthetic 
peptides
Biokit Spain
Chagas Hemagen Purified antigens Hemagen Diagnósticos USA
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Test Antigen Manufacturer Country
BioMérieux Total extract/RP BioMérieux France
BLK Total extract BLK diagnostics Spain
Siemens IMMULITE Chagas IgG RA Siemens Healthcare USA
Anti-Chagas Symbiosis NI Symbiosys Brazil
ORTHO T. cruzi ELISA Test System Total extract Jhonson and Jhonson USA
Certest (Strain Tulahuen 
and Mn)
Abbott Laboratories Spain
ImmunoComb II Chagas Ab RA/peptides Orgenics Israel
Elecsys Chagas assay Recombinant 
antigens
Roche Diagnostic
Gold ELISA Chagas Recombinant 
proteins and 
purified lysates
Brazil
ELISA Chagas III Total extract Grupo Bios Chile
Imuno-ELISA Chagas Recombinant 
antigens
Wama Diagnóstica Brazil
T. cruzi Ab, DIAPRO Recombinant 
antigens
Diagnostic BioProbes Italy
Trypanosoma cruzi IgG ELISA Kit Total extract MyBiosource USA
Chagas (Trypanosoma cruzi) IgG 
assay
NI DEMEDITEC 
Diagnostics GmbH
Germany
Chagas (Trypanosoma cruzi) IgG 
ELISA
NI GenWay Biotech, Inc. USA
Chagas (Trypanosoma cruzi) IgG 
ELISA
NI IBL International GmbH Germany
CELQUEST CHAGAS ELISA Recombinant 
antigens
ATGen Diagnostica Italy
Immunochromatographic assay
OnSite Chagas Ab Rapid test RA CTK Biotech USA
Chagas AB Rapid RA Standard Diagnostics Korea
WL Check Chagas RA Wiener Lab Argentina
Chagas Instantest Antigens attached 
to colloidal gold
Silanes Mexico
Prueba rápida Chagas Antigens attached 
to colloidal gold
Amunet Labarotarios Mexico
Chagas Detect™ Plus Multi-epitope
recombinant 
antigen
InBios, Inc. USA
Chagas-certum Antigens attached 
to colloidal gold
Certum® Diagnostics Mexico
Chagas Quick Test Multi-epitope
recombinant 
antigen
Cypress Diagnostic Belgium
Chagas Stat-Pak assay RA Chembio Diagnostic 
Systems
USA
PATH-Lemos rapid test RA Laboratório Lemos SRL Argentina
Immu-Sure Chagas (T. cruzi) Millennium Biotech USA
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Test Antigen Manufacturer Country
SD Chagas Ab Rapid RA Standard Diagnostic Korea
ICT Operon Purified antigens Operon Spain
Hemagglutination assays
Chagas HAI Imunoserum Sheep red 
blood cells are 
sensitized by 
binding
T. cruzi antigen
Laboratório Lemos SRL Argentina
ID-PaGIA, version 2 Ag/version 
3 Ag
RA/purified 
antigens
DiaMed Switzerland
Chagatest IHA Erythrocytes 
sensitized with 
parasite lysate
Wiener Argentina
Chagas HAI Bird red 
blood cells are 
sensitized by 
binding purified
T. cruzi (Y strain)
Ebram Brazil
Imuno-HAI Chagas Bird red 
blood cells are 
sensitized by 
binding purified
T. cruzi (Y strain)
WAMA Brazil
Chagas Hemagen HA Human red 
blood cells are 
sensitized by 
binding
epimastigote and 
amastigote forms 
of T. cruzi
(Y and CL strain)
Hemagen Diagnosticos USA
Hemacruzi Erythrocytes 
sensitized with 
parasite lysate
Biolab-Mérieux Brazil
ID-Chagas antibody test Gel particles 
coated with 
peptides
DiaMed-ID Switzerland
Serodia Chagas Gelatin particles 
coated with 
inactivated 
Trypanosoma 
cruzi antigens
Fujirebio, Inc. Japan
Immunofluorescence assays
Chagas IFA NI Vircell Spain
Inmunofluor Chagas kit Epimastigotes Biocientífica S.A Argentina
Kit Trypanosomiasis IFI Epimastigotes Tryniti-Mardx 
(Inverness Medical)
USA
Inmunofluor Chagas IFI Parasites NI Biocientífica S.A. 
(Inverness Medical)
Argentina
MarDx IFA MarDx Diagnostics, Inc. USA
IFA Kit Trypanosomiasis Innogenetics Ibérica Spain
Current Topics in Neglected Tropical Diseases
10
obtaining them, at lower cost and the presence of common antigens with trypomas-
tigotes [50]. Nevertheless, these tests also show cases of false negatives and cross-
reactivity [51–56]. Due to the complexity of the interaction of T. cruzi with its host, a 
single recombinant antigen has not reached the efficacy shown by the total extracts 
of the parasite. Thus, the antigenic composition of the tests based on recombinant 
antigens includes a combination of several epitopes [57]. Flow cytometry has mainly 
been used for differential diagnosis between Chagas disease and leishmaniasis owing 
to cross-reactivity. Even with optimized serological assays that use parasite-specific 
recombinant antigens, inconclusive test results continue to be a problem [58]. 
However, this technique is utilized for monitoring treatments rather than for diagno-
sis [59]. In the past decade, several technologies have emerged as diagnostic tools 
capable of improving diagnosis by using several antigens. The diagnostic process 
becomes faster and less expensive, and the hands-on time in laboratories decreases 
substantially since these platforms can be fully automated. A multiplex assay 
platform was evaluated to detect T. cruzi infection using the recombinant antigens 
CRA, FRA, CRA-FRA fusion and parasite lysate; these antigens presented different 
Test Antigen Manufacturer Country
Chemiluminescent immunoassay
Architect Chagas assay (prototype) 
immunoparticles
RA Abbott Laboratories Spain
CHAGAS VIRCLIA NI Vircell Spain
PCR assays
T. cruzi OligoC-TesT NA Coris BioConcept Belgium
AMPLIRUN® TRYPANOSOMA 
DNA CONTROL
NA Vircell Spain
Loop-mediated isothermal 
amplification (LAMP) assay
NA Eiken Chemical 
Company
China
RealCycler CHAG NA Progenie Molecular Spain
TCRUZIDNA.CE NA Diagnostic Bioprobes Srl Italy
RealStar® Chagas PCR Kit RUO NA altona Diagnostics 
GmbH
Germany
VIASURE Trypanosoma cruzi Real 
Time PCR Detection Kit
NA Certets Biotec Spain
Confirmatory assays
Radioimmunoprecipitation analysis 
[RIPA]
Radiolabeled T. 
cruzi
surface antigens
University of Iowa USA
INNO-LIA Chagas assay Recombinant and 
synthetic
T. cruzi antigens
Innogenetics Belgium
IF Imunocruzi Epimastigotes Biolab Mérieux Brazil
TESA-blot Excreted-secreted 
antigens
Biolab Mérieux Brazil
Multiplex Immunoassay Multi-cruzi 
(prototype)
Protein array NA NA
RA, recombinant antigen; NI, not indicated; NA, not applicable.
Table 2. 
List of commercial diagnostic tests for the serological detection of T. cruzi (Chagas disease).
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sensitivity and specificity by themselves; however, when mixed they increased its 
sensitivity and specificity, suggesting that they could be an alternative to single-test 
detection for Chagas disease [60]. Moreover, the immunochromatography represents 
a promising method which can be performed with whole blood, and it has many 
advantages over most existing diagnostic methods, requires little time, and does not 
require trained personnel; its main advantage is that it can be used in field work [61], 
but there are cases of discordance [62]. However, despite that, there are reports 
where it manifests that it no longer needed investing so much in research and 
development for the diagnosis of Chagas disease, because that rapid tests on the 
market are sufficiently valid both in America and in Europe and Asia-Pacific [63]; 
however, this is not entirely true, since several studies have shown discordance 
between the various commercial techniques. As mentioned, the diagnosis of Chagas 
disease is based mainly on serological tests because parasitemia is generally low or 
cannot be detected during the chronic phase of the infection. Finally, low reaction 
samples may not be detectable by all serological assays; besides, the presence of the 
so-called “serosilent” infections [64], in which parasitemia is detectable in seronega-
tive individuals, represents a potential risk to acquire the parasite.
2.2 The world of diagnosis for Chagas disease: a discordant paradise
The accurate diagnosis of T. cruzi infection is pivotal to the clinical manage-
ment of Chagas disease. T. cruzi has a complex life cycle, and its ability to infect 
any nucleated cell complicates diagnosis [65]. Additionally, the absence of a “gold 
standard” test that reliably and consistently detects the presence of a T. cruzi infec-
tion makes the evaluation of current methods difficult [28, 66]. Serodiscordance in 
Chagas disease remains a challenge since individuals with inconclusive results are 
clinically complicated to manage [67]; this problem usually arises in the diagnosis 
during the chronic phase. Performing two or more serological testing does not guar-
antee that the result shall be univocal. It is called serodiscordance when in the same 
patient two tests give different results (frequent situation during treatment, in preg-
nant patients or patient in acute cases), because the main criterion for “cure” has 
been the conversion to negative serology on all tests performed. However, this result 
is often not observed until 8–10 years posttreatment and then only in approximately 
15% of treated adult subjects [68]. Experts recommend that the IFI which has a 
sensitivity of 95% and a specificity of 100% is used. However, it is often not the 
most advisable since reading can be subjective, depending on the experience of the 
technician. Another situation that often occurs in reading spectrophotometric tests, 
such as ELISA, is that the values of optical density (OD) are very close to the cutoff 
value (±10%), in which case the result should not be considered positive or negative 
but rather indeterminate. Alternatives have been proposed as IFI, antigens’ parasite 
excretion-secretion (TESA) used in ELISA or immunoblot assays or by radioimmu-
noassay (RIPA), or various recombinant antigens used in immunoblot [14]. To date 
no test alone can establish the diagnosis or confirmation of infection by T. cruzi nor 
rule out the problem of cross-reactivity; the combination of tests usually generates 
discrepant results, often in a limited number of cases. Some commercial tests have 
very limited ability to detect T. cruzi infection in populations of particular study; 
internal tests based on crude parasite antigens showed a higher sensitivity but were 
still unable to detect all cases of T. cruzi infection [69], for example, the University 
of Sao Paulo conducted tests to detect T. cruzi antibodies using the three methods 
IH, IIF, and ELISA; 4000 serum samples were analyzed, of which only 1901 (48%) 
were positive for all three tests, 718 (18%) were negative, and 1381 (35%) had a 
questionable or inconclusive results. The discrepancies were attributable to the 
type of parasite antigen; IIF detects a specific antibody that reacts with a parasite 
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membrane antigen, whereas HI detects an antibody that reacts with a subcellular 
antigen. Each of these serological reactions operates in different specificity systems 
[70]. Another study in Spain was found to have a higher sensitivity (97–100%), 
and for serological screening of T. cruzi infection, a combination of tests is needed 
[71]. Finally, in a study conducted in a rural community in Veracruz, Mexico, using 
a combination of five ELISA tests based on different antigenic preparations (two 
in-house enzyme-linked immunosorbent assay based on crude extract, Chagatest 
ELISA recombinant v3.0, Chagatek ELISA, and NovaLisa Chagas), a very high level 
of discordance (32%) was also found among the ELISA tests used, with very poor 
agreement among them. This showed that the commercial tests had a very limited 
ability to detect T. cruzi infection, and the in-house tests based on crude parasite 
antigens showed a greater sensitivity but were still unable to detect all cases of T. 
cruzi infection, even when based on a local parasite strain [69].
To date, T. cruzi diagnostic present problems of sensitivity, making the diagnosis 
confusing and often requiring additional testing [40, 70, 71]. In congenital cases, it 
has been observed that discordance between the samples analyzed also occurs, and 
discordant results were confirmed by a third diagnostic test [72]. Although numer-
ous assays are available for diagnosing Chagas disease, no single test is considered 
the reference standard to confirm the diagnosis of infection by the parasite [73–76]. 
Serology is a useful tool in the diagnosis of Chagas disease, but in certain cir-
cumstances, none of the techniques described above serves as a marker of cure or 
progression of infection. Some authors mention that the Western blot is suitable for 
confirmation of infection by T. cruzi, so it is strongly recommended for confirma-
tion and discrimination of discordant cases [22, 77], because this technique has 
a sensitivity of 86.6% [20, 78], 99% [79], and 100% [80, 81] and a specificity of 
100%, making it more effective than techniques such as ELISA, HAI, and IIF. The 
adequate choice of T. cruzi strains as antigen source for the diagnosis of Chagas dis-
ease is still controversial due to differences in terms of accuracy reported between 
different diagnostic tests. The results of this study showed that the sensitivity index 
did not vary, with percentages of 100% for all strains in both tests. However, the 
specificity index for the ELISA tests showed differences between 92 and 98% but 
was reduced to 78–89% when the Leishmania-positive sera were included [82].
2.3 Looking for the correct diagnosis
After more than a century of the discovery of Chagas disease, there is no con-
sensus on the choice of a reference technique. Studies in South America reported a 
high efficiency of commercial kits manufactured in this region [40, 83]. However, 
work carried out in Central America shows that the use of antigens prepared from 
T. cruzi strains that are isolated in these areas increases the sensitivity of antibody 
detection assays [69, 84, 85]. This could be due to the predominance of the lineage 
TcI in the region [86] and the wide expansion of genotypes TcII–TcVI reported in 
the Southern Cone countries [87]; but lately, the presence of additional DTUs  
has been demonstrated in countries such as Mexico and the United States  
[88, 89]. The development of new diagnostics is partially limited by the availability 
of well-characterized antigens, in addition to the great variability among strains 
and DTUs in terms of virulence, infectivity, tissue tropism, progression of disease, 
drug susceptibility, and geographical distribution [31, 90–92]. However, there is 
as yet no clear association between genetic variants of the parasite and these life 
history or epidemiological characteristics. Several recombinant antigens that have 
serologic utility have been identified. However, the most effective antigens have 
been those with immunodominant, repeating B-cell epitopes [93]. The use of 
recombinant antigens and/or synthetic peptides has been proposed [94] to improve 
13
More than a Hundred Years in the Search for an Accurate Diagnosis for Chagas Disease: Current…
DOI: http://dx.doi.org/10.5772/intechopen.86567
specificity and sensitivity, which is essential if false-positive or false-negative 
results are to be avoided. Peptide analysis is a technique widely used for mapping of 
linear epitopes in proteins from pathogens [95, 96].
The recent availability of peptide microarrays allows rapid and inexpensive 
serological diagnosis with high performance [97, 98]. The availability of complete 
pathogen genomes has renewed interest in the development of diagnostics for 
infectious diseases. Synthetic peptide microarrays provide a rapid, high-throughput 
platform for immunological testing of potential B-cell epitopes. Therefore, compu-
tational approaches for prediction and/or prioritization of diagnostically relevant 
peptides are required [99]. Currently, high-density peptide chips for the discovery 
of linear B-cell epitopes’ specific pathogens from clinical samples provide the basis 
for the detection of biomarkers and proteome-scale studies of the immune response 
against pathogens [100].
The challenge for this process is to identify, by bioinformatics within a given 
proteome, peptides that could be good targets for a B-cell response. A number of 
algorithms have been developed for computational prediction of B-cell epitopes 
[101]. Computational prediction of B-cell epitopes is still an active research field, and 
a number of state-of-the-art predictors show improved performance [102–105]. As 
a consequence, predicting diagnostic epitopes in the context of a particular disease 
or infection is a complex problem, where many additional limitations are not taken 
into account, such as the mechanism of invasion of infectious agents, the expres-
sion pattern of parasite proteins. All these additional variables affect the outcome 
of the immune response and may explain the observed variability in responses [99]. 
In recent years, microarray technology has been of great interest, offering valuable 
opportunities to study the function of genes and the development of diagnostics. The 
main advantage of a microarray assay is to determine different analytes simultane-
ously, and it is more sensitive and faster than the conventional ELISA system. Peptide 
microarrays combined with a bioinformatics peptide selection strategy constitute a 
powerful and cost-effective platform for serodiagnostic biomarker screening of infec-
tious diseases just as Chagas disease [100]. The development of efficient methods 
for the detection of microspots with high sensitivity and specificity will enable new 
applications in future studies applied to protein microarrays [106, 107].
New-generation tests with potentially improved accuracy have been developed 
recently. The use of a large mixture of recombinant antigens and the incorporation 
of different detection systems, such as chemiluminescence, increase the sensitivity 
and specificity of the techniques. Other advantages of new-generation tests are 
automation, rapidity, and high performance, such as the Architect Chagas or Bio-
Flash Chagas (Biokit, Lliçà d’Amunt, Spain), which have improved the diagnosis of 
Chagas disease with innovative new tools (large mixture of recombinant antigens 
and chemiluminescence as detection system). Previous studies have also proposed 
a chemiluminescent ELISA (CL-ELISA) with purified trypomastigote glycoproteins 
for the detection of lytic protective antibodies against T. cruzi in human serum  
[35, 108–110]. Detection systems, such as chemiluminescence, increase light ampli-
fication and signal duration in comparison with traditional ELISAs, which may be 
a point in favor of these new methodologies, leading to higher accuracy in the diag-
nosis of Chagas disease. Further studies with other new-generation techniques with 
similar characteristics (recombinant antigens and chemiluminescence) are neces-
sary [35]. The use of a single technique would reduce diagnosis costs and therefore 
allow the application of screening and control programs in countries where such 
systems have not yet been implemented. Previous studies on the cost-effectiveness 
of Chagas disease management have been undertaken, but the costs of different 
diagnostic methods have not been compared [111–114]. Thus, several groups have 
implemented the usage of PCR to the identification of the genetic material from the 
Current Topics in Neglected Tropical Diseases
14
parasite, in blood and serum samples as well as tissue samples. Several types of the 
PCR techniques are available to detect T. cruzi DNA in serum and blood samples; 
among them we find conventional PCR, hot-start PCR, and nested PCR. Several 
tools that use probes to verify the presence/absence of specific DNA are also used; 
such as: Southern Blot or PCR and hybridization and real-time PCR. An important 
advantage that the use of PCR offers as a diagnosis tool is that it allows the char-
acterization of the circulating strains in an endemic area for Chagas disease [115]. 
Finally, there is a need to develop new non-serological non-PCR-based assays to 
address the limitations of the current methods available for T. cruzi detection. For 
this purpose, assays that detect biomarkers of Chagas disease need to be developed. 
Biomarker discovery studies reported for Chagas disease lead to the identification 
of characteristics of host origin, such as host proteins or immune markers, which 
were elevated in Chagas disease [116, 117]. However, one cannot exclude the pos-
sibility that these host markers could also be modulated in conditions unrelated to  
T. cruzi infection, and thus these biomarkers have limited specificity [118]. In order 
to overcome the issues of specificity, the detection of pathogen-specific factors 
would be ideal biomarkers of T. cruzi infection [33].
3. Conclusions
Chagas disease causes 12,000 deaths each year, and it is estimated that between 
7 and 8 million people suffer. This is one of the major public health problems in 
Latin America. In recent decades, cases have also been detected in North America, 
Europe, and Asia-Pacific, mainly as a result of migration. An ideal serological test 
should be easy to perform in a single step, be fast, and be cheap, require no special 
equipment or refrigeration of reagents, and have 100% sensitivity and specific-
ity; unfortunately, no such test exists for Chagas disease. The lack of a reference 
standard serological assay for the diagnosis of T. cruzi infection has prompted the 
development of new tests, which require further evaluation, so that the develop-
ment of diagnostic methods for detecting T. cruzi infections, after more than a 
hundred years of its discovery, remains a challenge which depends mainly on the 
availability of specific high-affinity antigens. The diagnosis of Chagas disease has 
limitations, mainly due to the great complexity of the factors that involve it, as well 
as to the low sensitivity of the parasitological techniques and the low specificity of 
the immunological tests. Finally, the application of immunomics, which combines 
serology with proteomics, would help to discover genes and molecules related to 
the susceptibility and immunity of T. cruzi infection, allowing the creation of an 
adequate diagnosis for the disease, elucidating new therapeutic targets, and, why 
not, allowing the creation of a vaccine against Chagas disease.
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